Harmony Biosciences
Harmony Biosciences Appoints Peter Anastasiou President and Chief Executive Officer
Harmony Biosciences announced a leadership change on October 12, 2026. Harmony Biosciences appointed Chief Operating Officer Peter Anastasiou as CEO effective January 1, 2027, succeeding retiring CEO Jeffrey M. Dayno, to lead the company’s next phase of growth.
What changed
Peter Anastasiou was named President and Chief Executive Officer. Jeffrey M. Dayno, M.D., will retire as President and CEO at the end of 2026, step down from the Board on December 31, 2026, and serve as a non-executive advisor to the company throughout 2027.
- Leader: Peter Anastasiou
- Role: President and Chief Executive Officer
- Effective: January 1, 2027
- Announcement date: October 12, 2026
Leadership background
Anastasiou is Harmony’s Senior Executive Vice President and Chief Operating Officer and previously served on its Board for three years. He was CEO and a board member of Capsida Biotherapeutics for nearly four years, and earlier was Executive Vice President, a member of the global executive committee, and President of North America at Lundbeck. Earlier roles include management positions at Neuronetics, Bristol-Myers Squibb, and Lilly.
The mandate
Harmony said it remains focused on growing the pitolisant franchise, advancing its CNS pipeline led by BP-205, deploying capital by transacting on value-creating assets, and protecting WAKIX exclusivity. Anastasiou said he looks forward to leading Harmony through its next phase of growth.
Why this matters for GTM teams
Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.
Source and methodology
This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.
Primary source: Harmony Biosciences leadership announcement.
Related Reports
Asembia Appoints David Skomo Chief Executive Officer
Asembia appointed David Skomo as CEO, succeeding co-founder Lawrence Irene, and said he will focus on strengthening the company’s commercial capabilities, technology platform, and pharmacy services.
Lassila and Tikanoja Appoints Ari-Pekka Määttänen President and CEO
Lassila and Tikanoja appointed Ari-Pekka Määttänen, CEO of Fintoil Oy, as President and CEO from May 1, 2027, succeeding Eero Hautaniemi to lead the circular economy company’s next phase of growth.
Sciensus Appoints James Tugendhat Chief Executive Officer
Sciensus has appointed James Tugendhat OBE, most recently Group CEO of HC-One, as Chief Executive Officer, taking over from interim CEO Gordon Cox.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started


